N 0861

CAS No. 141696-90-4

N 0861( —— )

Catalog No. M36353 CAS No. 141696-90-4

N 0861 is a selective adenosine A1 receptor antagonist that attenuates renal insufficiency during adenosine-controlled hypotension in rats.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 246 In Stock
5MG 411 In Stock
10MG 562 In Stock
25MG 866 In Stock
50MG 1097 In Stock
100MG 1469 In Stock
200MG 2009 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    N 0861
  • Note
    Research use only, not for human use.
  • Brief Description
    N 0861 is a selective adenosine A1 receptor antagonist that attenuates renal insufficiency during adenosine-controlled hypotension in rats.
  • Description
    N 0861 is a selective adenosine A1 receptor antagonist that attenuates renal insufficiency during adenosine-controlled hypotension in rats.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    GPCR/G Protein
  • Target
    Adenosine Receptor
  • Recptor
    Adenosine Receptor
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    141696-90-4
  • Formula Weight
    243.31
  • Molecular Formula
    C13H17N5
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    N(C1=C2C(N(C)C=N2)=NC=N1)[C@H]3[C@@]4(C[C@](C3)(CC4)[H])[H]
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • CGS 21680

    CGS 21680 is a specific adenosine A2A subtype receptor agonist with Ki of 27 nM.

  • N6-Cyclopentyladenos...

    N6-Cyclopentyladenosine (CPA) is a selective agonist of the adenosine A1 receptor, mimicking its action with Ki values of 2.3 nM, 790 nM, and 43 nM for human A1, A2A, and A3 receptors, respectively.

  • 2-Cl-IB-MECA

    2-Cl-IB-MECA (Chloro-IB-MECA, CF-102, Namodenoson) is a potent, selective A3 adenosine receptor agonist with Ki of 0.33 nM, 2500- and 1400-fold selectivity over A1 and A2a receptors.